Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: $Mogul who wrote (2942)	3/9/1999 6:29:00 PM
From: True Grit	Respond to of 3702

Looks to me like a classic case of economic hypothermia. TCLN's body temperature appears to have dropped so low that it can not recover without outside heat. And outside heat (investment) means more dilution to existing stockholders. A buy-out offer seems ever more likely, I agree. Only way to stop a hostile takeover at this point is to either take on more debt (unlikely) or license out existing technology so that there is nothing left for an outsider to "steal." Thus, I'm looking for a lot of licensing deals in the next few months -- for more reasons than simple cash flow. TCLN is exchanging its rapidly dwindling current equity for outside credibility. Short term, I don't see much gain for the Company, because Ed Legere has to be paid off for his European rights to Lym-1. Sure, TCLN will make money on the mfg of the drug, but that's a long way off. Management has no other choice at this point but concentrate on saving itself, even if it means shutting off circulation to some of its limbs. Survival is all that matters. Smart move, at this point. IMHO. Best wishes to all, True Grit